Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
OptimizeRx Analyst Ratings and Price Targets | NASDAQ:OPRX | Benzinga
OptimizeRx Corp has a consensus price target of $17.14 based on the ratings of 11 analysts. The high is $56 issued by B. Riley Securities on July 20, 2022. The low is $5 issued by Barclays on November 14, 2024. The 3 most-recent analyst ratings were released by Stifel, Stifel, and JMP Securities on June 9, 2025, May 13, 2025, and May 13, 2025, respectively. With an average price target of $14.17 between Stifel, Stifel, and JMP Securities, there's an implied 6.64% upside for OptimizeRx Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
JMP Securities
RBC Capital
Lake Street
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for OptimizeRx
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/09/2025 | Buy Now | 20.44% | Stifel | David Grossman66% | $12.5 → $16 | Maintains | Buy | Get Alert |
| 05/13/2025 | Buy Now | -5.91% | Stifel | David Grossman66% | $8 → $12.5 | Maintains | Buy | Get Alert |
| 05/13/2025 | Buy Now | 5.38% | JMP Securities | Constantine Davides42% | $11 → $14 | Maintains | Market Outperform | Get Alert |
| 02/06/2025 | Buy Now | -39.78% | JMP Securities | Constantine Davides42% | $8 → $8 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/08/2025 | Buy Now | -54.84% | RBC Capital | Sean Dodge48% | $7 → $6 | Downgrade | Outperform → Sector Perform | Get Alert |
| 12/24/2024 | Buy Now | -17.2% | Lake Street | Eric Martinuzzi57% | $11 → $11 | Reiterates | Buy → Buy | Get Alert |
| 12/24/2024 | Buy Now | -2.15% | B. Riley Securities | Neil Chatterji37% | $17 → $13 | Maintains | Buy | Get Alert |
| 12/20/2024 | Buy Now | -58.6% | Stephens & Co. | Jeff Garro37% | → $5.5 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2024 | Buy Now | -39.78% | JMP Securities | Constantine Davides42% | $16 → $8 | Maintains | Market Outperform | Get Alert |
| 11/14/2024 | Buy Now | -47.31% | RBC Capital | Sean Dodge48% | $14 → $7 | Maintains | Outperform | Get Alert |
| 11/14/2024 | Buy Now | 20.44% | Roth MKM | Richard Baldry40% | $20 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/14/2024 | Buy Now | -39.78% | Stifel | David Grossman66% | $13 → $8 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | -62.36% | Barclays | Stephanie Davis44% | $11 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/16/2024 | Buy Now | 5.38% | RBC Capital | Sean Dodge48% | $17 → $14 | Maintains | Outperform | Get Alert |
| 08/12/2024 | Buy Now | -17.2% | Barclays | Stephanie Davis44% | $15 → $11 | Maintains | Equal-Weight | Get Alert |
| 06/24/2024 | Buy Now | 20.44% | JMP Securities | Constantine Davides42% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/21/2024 | Buy Now | 20.44% | JMP Securities | Constantine Davides42% | $16 → $16 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | 20.44% | JMP Securities | Constantine Davides42% | $15 → $16 | Maintains | Market Outperform | Get Alert |
| 05/15/2024 | Buy Now | -2.15% | Stifel | David Grossman66% | $13 → $13 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 12.91% | JMP Securities | Constantine Davides42% | $15 → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/04/2024 | Buy Now | 12.91% | JMP Securities | Constantine Davides42% | → $15 | Initiates | → Market Outperform | Get Alert |
| 04/01/2024 | Buy Now | 27.96% | RBC Capital | Sean Dodge48% | $17 → $17 | Reiterates | Outperform → Outperform | Get Alert |
| 04/01/2024 | Buy Now | -2.15% | Stifel | David Grossman66% | $13 → $13 | Maintains | Buy | Get Alert |
| 01/10/2024 | Buy Now | 27.96% | RBC Capital | Sean Dodge48% | $14 → $17 | Maintains | Outperform | Get Alert |
| 01/03/2024 | Buy Now | 12.91% | Barclays | Stephanie Davis44% | → $15 | Initiates | → Equal-Weight | Get Alert |
| 08/15/2023 | Buy Now | 5.38% | RBC Capital | Sean Dodge48% | $18 → $14 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | -2.15% | Lake Street | Eric Martinuzzi57% | $18 → $13 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 50.55% | Roth MKM | Richard Baldry40% | $31 → $20 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 35.49% | B. Riley Securities | Neil Chatterji37% | $28 → $18 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | -2.15% | Stifel | David Grossman66% | $16 → $13 | Maintains | Buy | Get Alert |
| 03/09/2023 | Buy Now | 35.49% | RBC Capital | Sean Dodge48% | $22 → $18 | Maintains | Outperform | Get Alert |
| 02/02/2023 | Buy Now | 125.82% | B. Riley Securities | Neil Chatterji37% | → $30 | Reinstates | → Buy | Get Alert |
| 11/01/2022 | Buy Now | 43.02% | Stifel | David Grossman66% | → $19 | Initiates | → Buy | Get Alert |
| 10/31/2022 | Buy Now | 43.02% | Stifel | David Grossman66% | → $19 | Initiates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | 65.6% | RBC Capital | Sean Dodge48% | $50 → $22 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 20.44% | Piper Sandler | Jeff Garro37% | $29 → $16 | Maintains | Neutral | Get Alert |
| 08/10/2022 | Buy Now | 125.82% | SVB Leerink | Joy Zhang26% | $38 → $30 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | 321.53% | B. Riley Securities | Marc Wiesenberger75% | $71 → $56 | Maintains | Buy | Get Alert |
| 07/15/2022 | Buy Now | 186.04% | SVB Leerink | Joy Zhang26% | → $38 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for OptimizeRx (OPRX) stock?
The latest price target for OptimizeRx (NASDAQ:OPRX) was reported by Stifel on June 9, 2025. The analyst firm set a price target for $16.00 expecting OPRX to rise to within 12 months (a possible 20.44% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for OptimizeRx (OPRX)?
The latest analyst rating for OptimizeRx (NASDAQ:OPRX) was provided by Stifel, and OptimizeRx maintained their buy rating.
When was the last upgrade for OptimizeRx (OPRX)?
There is no last upgrade for OptimizeRx
When was the last downgrade for OptimizeRx (OPRX)?
The last downgrade for OptimizeRx Corp happened on January 8, 2025 when RBC Capital changed their price target from $7 to $6 for OptimizeRx Corp.
When is the next analyst rating going to be posted or updated for OptimizeRx (OPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OptimizeRx, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OptimizeRx was filed on June 9, 2025 so you should expect the next rating to be made available sometime around June 9, 2026.
Is the Analyst Rating OptimizeRx (OPRX) correct?
While ratings are subjective and will change, the latest OptimizeRx (OPRX) rating was a maintained with a price target of $12.50 to $16.00. The current price OptimizeRx (OPRX) is trading at is $13.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
